卡维地洛治疗原发性高血压疗效分析

The therapeutic effect ot carvedilol for the treatment of essential hypertension

目的评价卡维地洛对原发性高血压的临床疗效及安全性。方法60例原发性高血压患者,经过2周安慰剂洗脱期后随即分为治疗组和对照组,对照组30例给予美托洛尔25 mg,2次/d,口服2周末血压下降未达到有效标准者增至50 mg,2次/d,疗程8周;治疗组30例给予卡维地洛10 mg,2次/d,服药2周末血压标准未达到有效标准者增至20 mg,2次/d,疗程共8周。结果治疗组降压总有效率80.0%,显效率56.7%,对照组总有效率73.3%,显效率53.3%;2组疗效比较差异无统计学意义(P>0.05),不良反应发生率差异无统计学意义(P>0.05)。2组不良反应程度均较轻,可耐受。结论卡维地洛是治疗原发性高血压安全有效的药物。

Objective To evaluate the efficacy and safety of carvedilol in the treatment of essential hypertension, Methods After two weeks/washing out period ,sixty patients with essential hypertension were equally randomized to orally take carvedilol（10mg,bid ） or metoprelol（25mg ,bid ） for two weeks. If the patients did not respond to the two weeks＇therapy ,the dosages of carvedilol or metoprelol were escalate to 50mg bid and 20 mg bid for 8 weeks ,respectively, Results At the end of 8 weeks＇therapy, patients treated with carvedilol and metoprelol achieved overall response rate at 80.8% and 73.3% （P 〉0. 05） ,respectively . The carvedilol was well tolerated with mild side effects. Conclusion Carvedilol is effective and safe in the treatment of essential hypertension.